マルチプルミエロマ (多発性ミエロマ) とは
Marc S Raab1, Klaus Podar, Iris Breitkreutz
1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Lancet (London, England)
|June 23, 2009
まとめ
多発性骨髄腫は,悪性プラズマ細胞と骨髄の微小環境を含む. 両方を標的とする新型の治療法は,多発性骨髄腫および他の癌の患者のアウトカムを改善します.
科学分野:
- 腫瘍学 腫瘍学
- 血液学 ヘマトロジ
背景:
- 多発性骨髄腫は,悪性プラズマ細胞の癌である.
- 骨髄の微小環境は,骨髄腫の発達と進行において重要な役割を果たします.
研究 の 目的:
- 多発性骨髄腫の病原性における骨髄マイクロ環境の役割を検討する.
- 骨髄腫細胞とそのマイクロ環境の両方を標的とした新しい治療薬の影響を強調する.
主な方法:
- 多発性骨髄腫とその治療に関する既存の文献のレビュー.
- タリドマイド,ボルテゾミブ,レーナリドマイドなどの薬剤の作用機構の分析.
主要な成果:
- 骨髄のマイクロ環境と骨髄腫細胞をターゲットにすることで,治療効果が向上します.
- タリドマイド,ボルテゾミブ,レーナリドマイドなどの薬剤は,有意な効果を示しています.
- これらの薬剤は,全体的な応答,応答の持続時間,進行性のない生存率,および全体的な生存率を改善します.
結論:
- 骨髄のマイクロ環境は,多発性骨髄腫における重要な治療目標である.
- これらの新薬をファーストラインの治療計画に組み込むことは,患者にとって改善された結果をもたらします.
- この治療アプローチは,他の血液学的悪性腫瘍や固体腫瘍にも有望である.
関連する概念動画
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:27Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...